FDA Approval Clears Abbott's Drug-Eluting Stent for Immediate Launch in US

In Cardio
Fri, 4 Jul 2008

Abbott's drug-eluting stent (DES) is the fourth on the US market after the Cordis Cypher stent, Boston Scientific's Taxus stent, and Medtronic's Endeavor stent. In two randomised clinical trials, Xience V demonstrated superiority over Boston Scientific's Taxus coronary stent system.

The clinical programme for Xience V includes long-term data from a total of 1,362 patients enrolled in the SPIRIT I, SPIRIT II and SPIRIT III trials, as well as continued access and post-approval programs that will enroll more than 14,000 Xience V patients.

«« Study Shows Heart Scan with Lower Dose Enabled by Dual-Source CT

Basic Neurological Test May Identify High-Risk Stroke Candidates »»

Latest Articles

Decision-Making in the ICU
- Journal Article
- 19/04/2024
Decision-making in the ICU is a multifaceted process that involves clinical assessment, collaboration among multidisciplinary teams, ethical considerations, evidence-based practice, communication, and continuous adaptation to evolving clinical scenarios. Balancing the complex factors requires
READ MORE
Dealing With Uncertainty in ICU Decision-Making: A Practical Guide
- Journal Article
- 19/04/2024
When the stakes are high, and the path ahead is uncertain, the decisions made, especially if a patient continues to worsen, can be sources of self-torment and can haunt us for a long time. Our goal is to suggest ways to steer decision-making for intensivists in the face of uncertainty by prop
READ MORE
The Least Bad Decision: Crisis Standards of Care After the Pandemic
- Journal Article
- 19/04/2024
COVID-19 was an emergency that lasted for years and left few regions of the world untouched. The pandemic shone a spotlight on both the strengths and weaknesses of our disaster planning. What worked, what did not, and how can we better plan for future emergencies? The COVID-19 pandemic fo
READ MORE

Abbott's drug-eluting stent (DES) is the fourth on the US market after the Cordis Cypher stent, Boston Scientific's Taxus stent, and Medtronic's Endeavor...